MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$16M
Free Cash flow
$65M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
Net income
Trade accounts payable
Amortization
Others
Negative Cash Flow Breakdown
Accounts receivable
Other current assets
Capital expenditures
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
108
146
-205
160
Depreciation
34
39
46
40
Amortization
46
47
50
52
Impairment of assets
0
-
0
0
Acquired in-process research and development and milestones
1
0
0
0
Accretion and changes in fair value in contingent consideration
-9
5
41
32
Deferred income tax expense (benefit)
16
3
30
40
Stock-based compensation
25
19
7
24
Unrealized foreign exchange (gain) loss
12
-3
13
9
Gain on sale of jada
0
81
-
-
Gain on debt repurchase
0
-
27
0
Impairment of goodwill
-
-
301
-
Other Noncash Income Expense
-5
-12
-27
-16
Accounts receivable
111
65
-160
5
Inventories
15
9
-81
63
Other current assets
76
15
-22
-24
Trade accounts payable
74
32
-120
12
Accrued and other current liabilities
-20
95
-156
73
Income taxes payable
7
-4
-31
-76
Increase Decrease In Other Operating Capital Net
-16
-8
-10
-8
Net cash flows provided by operating activities
107
225
141
264
Capital expenditures
42
37
45
46
Proceeds from sale of property, plant and equipment
0
-
0
0
Acquired in-process research and development and milestones
0
10
20
0
Proceeds from sale of jada
0
433
-
-
Dermavant acquisition, net of cash acquired
0
0
0
0
Purchase of product rights and asset acquisition
34
0
0
69
Net cash flows provided by (used) in investing activities
-76
386
-65
-115
Proceeds from debt
0
0
325
300
Repayments of debt
0
32
507
372
Payment of long-term debt issuance costs
-
-
0
0
Employee withholding taxes related to stock-based awards
6
1
1
1
Dividend payments
6
5
4
3
Net cash flows used in financing activities
-12
-38
-187
-76
Effect of exchange rate changes on cash and cash equivalents
-3
-31
13
0
Net increase (decrease) in cash and cash equivalents
16
542
-98
73
Cash and cash equivalents, beginning of period
1,116
574
547
547
Cash and cash equivalents, end of period
1,132
1,116
574
672
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income
$108M
(-25.52%↓ Y/Y)
Trade accounts
payable
$74M
(85.00%↑ Y/Y)
Amortization
$46M
(-13.21%↓ Y/Y)
Depreciation
$34M
(-5.56%↓ Y/Y)
Stock-based compensation
$25M
(13.64%↑ Y/Y)
Increase Decrease In
Other Operating...
-$16M
(80.25%↑ Y/Y)
Deferred income tax
expense (benefit)
$16M
(60.00%↑ Y/Y)
Accretion and changes in
fair value in...
-$9M
(25.00%↑ Y/Y)
Income taxes payable
$7M
(-12.50%↓ Y/Y)
Other Noncash Income
Expense
-$5M
(79.17%↑ Y/Y)
Acquired in-process
research and development...
$1M
Net cash flows
provided by operating...
$107M
(-51.36%↓ Y/Y)
Canceled cashflow
$234M
Net increase
(decrease) in cash and cash...
$16M
(-69.23%↓ Y/Y)
Canceled cashflow
$91M
Accounts receivable
$111M
(1333.33%↑ Y/Y)
Other current assets
$76M
(13.43%↑ Y/Y)
Accrued and other
current liabilities
-$20M
(79.59%↑ Y/Y)
Inventories
$15M
(-55.88%↓ Y/Y)
Unrealized foreign
exchange (gain) loss
$12M
(175.00%↑ Y/Y)
Net cash flows
provided by (used) in...
-$76M
(-100.00%↓ Y/Y)
Net cash flows used
in financing...
-$12M
(94.62%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
-$3M
(-103.23%↓ Y/Y)
Capital expenditures
$42M
(7.69%↑ Y/Y)
Purchase of product
rights and asset...
$34M
Dividend payments
$6M
(-40.00%↓ Y/Y)
Employee withholding
taxes related to...
$6M
(-50.00%↓ Y/Y)
Buy us a coffee
organon-logo-svg
Organon & Co. (OGN)
organon-logo-svg
Organon & Co. (OGN)